Effect of once-weekly subcutaneous semaglutide on arterial inflammation in people with type 2 diabetes and cardiovascular disease using PET-MRI: Primary results of a randomized, double-blind, placebo-controlled trial

What Was Tested

The paper reports a study of Semaglutide, published as a randomized controlled trial.

The primary and key secondary endpoints used PET-MRI with [18F]FDG and [68Ga]DOTATATE tracers to assess change from baseline to week 26 in plaque inflammation in the segments of the carotid arteries that were determined to be the most diseased and where plaque inflammation was quantified by the maximum target-to-background ratio (TBRmax) of the tracers.

Why It Was Studied

This trial investigated the effect of semaglutide on atherosclerotic inflammation in the carotid arteries using positron emission tomography (PET)-magnetic resonance imaging (MRI).

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The participants were allocated by chance, so the Semaglutide group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Semaglutide, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Semaglutide could be set against what happens without it.

Additional secondary endpoints assessed plaque morphology and burden using MRI at week 52, including total wall volume, lipid-rich necrotic core volume, and fibrous cap thickness.

What Was Measured

The subject headings attached to it are Cardiovascular Diseases, Diabetes Mellitus, Type 2, Fluorodeoxyglucose F18, Glucagon-Like Peptides, Magnetic Resonance Imaging, Organometallic Compounds and Plaque, Atherosclerotic.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Semaglutide.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (American heart journal), a journal based in United States.

More context: the Semaglutide compound page, all human trials.